About Pfizer Venture Investments
Pfizer Venture Investments is a venture capital firm founded in 2004. It is primarily based out of New York City, United States. As of Jan 2026, Pfizer Venture Investments is an active investor, having invested in 73 companies, with 1 new investment in the last 12 months. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Series B round of TRexBio Overall, Pfizer Venture Investments portfolio has seen 18 IPOs and 19 acquisitions including key companies like Medtronic, CytomX Therapeutics and BioNTech. A lot of funds co-invest with Pfizer Venture Investments, with names like AbbVie sharing a substantial percentage of its portfolio. Pfizer Venture Investments has team of 1 people including 1 partners.Key Metrics
Team Members
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 5 more
Portfolio IPOs
Portfolio Soonicorns
Deals in last 12 months
Pfizer Venture Investments' List of Top Investments
Pfizer Venture Investments has a portfolio of 73 companies. Their most notable investments are in Nimbus Therapeutics and Nimbus Therapeutics.Their portfolio spans across United States, United Kingdom, Switzerland and 5 more locations. They have invested in Life Sciences, High Tech, Enterprise Applications and 6 other sectors, across stages such as Series A, Series B and 5 more. Here is the list of top investments by Pfizer Venture Investments:1. Medtronic
Developer of medical equipment for chronic diseases. The company offers solutions to treat more than 30 chronic diseases, including heart failure, Parkinson's disease, urinary incontinence, Down's syndrome, obesity, neurology, chronic pain, spinal disorders, and diabetes. In general surgery products, the company has developed intraoperative neuromonitoring devices, ablation systems, neurostimulation systems, and others. In 2022, the company recorded annual revenues of $30.77B and a net profit of $4.07B.
Key facts about Medtronic
- Founded Year: 1949
- Location: Minneapolis (United States)
- Annual Revenue: $12.5B as on Apr 30, 2025
- Stage: Public
- Employee Count: 101,924 as on Mar 31, 2026
- Investors: Saints Capital, Greyrock Investments and 23 Others
- Latest Funding Round: Grant (prize money), Oct 01, 2022, $*****
- Highlight: Public
2. RefleXion
Provider of biology-guided radiotherapy system. Its patented technology leverages Positron Emission Tomography (PET) which allows tumors to continuously signal their location during treatment and guides personalized radiation therapy. The technology has applications in the treatment of Lung, prostate, and Breast cancers.
Key facts about RefleXion
- Founded Year: 2009
- Location: Hayward (United States)
- Stage: Series F
- Total Funding till date: $542M
- Employee Count: 166 as on Mar 31, 2026
- Investors: PSP Investments, GT Healthcare Capital Partners and 24 Others
- Latest Funding Round: Series F, Nov 13, 2023, $*****
- Highlight: Editors' Pick
Developing probody therapeutics to treat cancer. The company is utilizing Probody platform to develop potential best-in-class therapies against clinically validated targets solid tumors and lung cancers.
Key facts about CytomX Therapeutics
- Founded Year: 2008
- Location: Santa Barbara (United States)
- Annual Revenue: $138M as on Dec 31, 2024
- Stage: Public
- Total Funding till date: $136M
- Employee Count: 99 as on Mar 31, 2026
- Investors: Fidelity Investments, Wellington and 14 Others
- Latest Funding Round: Series D, Jun 25, 2015, $*****
- Highlight: Public
4. BioNTech
Developer of immunotherapeutics for the treatment of cancer and other diseases. Its oncology drug pipeline contains several classes of drugs which include mRNA treatments, modified cell therapies, antibodies, and small molecule immunomodulators that have been optimised for distinct modes of action, high precision targeting, potency, and efficacy.
Key facts about BioNTech
- Founded Year: 2008
- Location: Mainz (Germany)
- Stage: Public
- Total Funding till date: $861M
- Employee Count: 5,101 as on Mar 31, 2026
- Investors: EIP, Fidelity Investments and 28 Others
- Latest Funding Round: Post IPO, Apr 14, 2022, $*****
- Highlight: Public
Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases. The lead candidate targets ACC for Nonalcoholic Steatohepatitis (NASH). The other drug candidate is an IRAK4 inhibitor used to target Tyk2 and KRas that mediates immune signaling.
Key facts about Nimbus Therapeutics
- Founded Year: 2009
- Location: Cambridge (United States)
- Stage: Series F
- Total Funding till date: $637M
- Employee Count: 101 as on Mar 31, 2026
- Investors: BVF Partners, Access Industries and 20 Others
- Latest Funding Round: Series F, Sep 06, 2023, $*****
- Highlight: Editors' Pick
Pfizer Venture Investments' Year-on-Year Investment Trends
Pfizer Venture Investments has invested in 73 companies over the last 21 years, with an average of 3 new investments annually in the last 10 years. In 2025, it made 2 investments, while as of Jan 2026, it has made 1 investment in this year. Its most recent first time investment was in TRexBio and most recent follow-on round was in Mission Therapeutics.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 1 | 0 | 1 |
2025 | 1 | 1 | 2 |
2024 | 1 | 1 | 2 |
2023 | 0 | 0 | 0 |
2022 | 2 | 0 | 2 |
2021 | 1 | 1 | 2 |
2020 | 4 | 2 | 6 |
2019 | 1 | 1 | 2 |
2018 | 6 | 5 | 11 |
2017 | 7 | 4 | 11 |
Pfizer Venture Investments' Investments by Stage
Pfizer Venture Investments has made 24 investments in Series A stage with an average round size of $31.5M, 21 investments in Series B stage with an average round size of $46.8M and 5 investments in Series C stage with an average round size of $45.9M.Stage of entry | No. of Investments |
|---|---|
Series A | 24 |
Series B | 21 |
Series C | 5 |
Seed | 3 |
PE | 1 |
Others | 2 |
Note: We have considered here, only first round of investments
Pfizer Venture Investments' Investments by Sector
Pfizer Venture Investments has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Enterprise Applications, HealthTech and Healthcare. Notably, it has invested in 66 Enterprise (B2B) companies, 61 Tech companies, 10 Software companies and at least 4 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 51 |
High Tech | 11 |
Enterprise Applications | 5 |
HealthTech | 4 |
Healthcare | 3 |
Others | 10 |
Note: We have considered here, only first round of investments
Pfizer Venture Investments' Investments by Geography
Pfizer Venture Investments has made most investments in United States (44), followed by United Kingdom where it has made 4 investments.Country | No. of Investments |
|---|---|
United States | 44 |
United Kingdom | 4 |
Israel | 2 |
Switzerland | 2 |
China | 1 |
Others | 3 |
Note: We have considered here, only first round of investments
Pfizer Venture Investments' recent investments
Pfizer Venture Investments has made 1 investments in 2026 so far - TRexBio.Here are the most recent investments by Pfizer Venture Investments:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jan 27, 2026 | United States | Series B | 5456 | ||
Oct 15, 2025 | United Kingdom | Series D | 1491 | [+4] | |
Jan 13, 2025 | United States | Series B | 4646 | [+8] | |
May 23, 2024 | United Kingdom | Series B | 9158 | [+5] | |
Mar 14, 2024 | United Kingdom | Series D | 3655 | [+4] |
IPOs and Publicly Listed companies in Pfizer Venture Investments' Portfolio
18 of Pfizer Venture Investments' portfolio companies have become public. Bolt Biotherapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Feb 2021 at marketcap of $690M and BioAtla got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $578M.Here are Pfizer Venture Investments' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Feb 05, 2021 | Jul 01, 2020 | Series C | 8162 | |
Dec 16, 2020 | Jul 15, 2020 | Series D | 1266 | |
Dec 11, 2020 | Jan 08, 2016 | Series A | 4638 | |
Aug 21, 2020 | Nov 13, 2018 | Series B | 5745 | |
Mar 12, 2020 | Apr 14, 2016 | Series A | 3952 |
Acquired companies in Pfizer Venture Investments' Portfolio
19 companies from Pfizer Venture Investments' portfolio have been acquired. The most recent acquisition was Merus in Dec 2025 by Genmab for $*****.Here are Pfizer Venture Investments' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Dec 12, 2025 | Oct 03, 2013 | Series B | 2708 | |
Nov 13, 2025 | Jul 31, 2012 | Series A | 2865 | |
Jul 08, 2024 | Jun 30, 2016 | Series A | 9465 | |
Oct 05, 2023 | - | - | 5597 | |
May 21, 2023 | - | - | 7593 |
Team profile of Pfizer Venture Investments
Pfizer Venture Investments has a team of 1 member located in United States. Pfizer Venture Investments' team does not sit on the board of any company as of now.Co-investors of Pfizer Venture Investments
Over the past 21 years, 390 investors have co-invested in Pfizer Venture Investments's portfolio companies. This includes funds and angels.
- Invested before Pfizer Venture Investments: Pfizer, HHS and 99 others have invested in rounds before Pfizer Venture Investments. There are 6 companies where Pfizer has invested before Pfizer Venture Investments and 4 companies where HHS has invested before Pfizer Venture Investments.
- Top Co-investors of Pfizer Venture Investments: 131 investors entered a company along with Pfizer Venture Investments. These include investors like AbbVie (7 companies).
- Invested after Pfizer Venture Investments: A total of 158 investors have invested in Pfizer Venture Investments's portfolio after their investments. Top Investors include Pfizer (7 companies), RA Capital Management (5 companies) and Wellington (4 companies).
Recent News related to Pfizer Venture Investments
•
4DMT goes forward with $75mGlobal Corporate Venturing•Jun 17, 2020•4D Molecular Therapeutics, Chiesi Ventures, Pfizer Venture Investments, Viking Global Investors and 2 others
•
STORM Therapeutics Extends Series A to GBP 30M (USD 38.43M) with New Investor, Seroba Life SciencesPR Newswire•May 20, 2019•Storm Therapeutics, Seroba Lifesciences, Cambridge Innovation Capital, M Ventures and 4 others
•
Pfizer, Astellas peg Xtandi expansion on PROSPER dataBioPharmaDive•Feb 05, 2018•Pfizer Venture Investments, Astellas Pharma
•
Pfizer benefits from tax reform, still vague on M&ABioPharmaDive•Jan 30, 2018•Pfizer Venture Investments
•
•
•
Rhythm Closes $41M Mezzanine FinancingFinSMEs•Feb 16, 2017•Rhythm Pharmaceuticals, Deerfield, Ipsen, Orbimed and 2 others
